Table 1.
Baseline demographic and clinical characteristics of patients before and after propensity score matched analysis
| Before matching | Propensity score matched | |||||
|---|---|---|---|---|---|---|
| Characteristics | DAP (N = 28) | VAN (N = 44) | p | DAP (N = 16) | VAN (N = 16) | p |
| Male sex, n (%) | 17 (61) | 34 (77) | .215 | 10 (63) | 11 (69) | 1 |
| Age, y | 60.0 [52.3–70.5] | 63.0 [54.0–75.3] | .206 | 56.0 [49.5–69.3] | 65.0 [49.0–78.0] | .086 |
| Weight, kg | 74.0 [61.5–80.5] | 72.0 [64.5–80.0] | .827 | 71.5 [61.5–79.3] | 75.0 [63.0–85.3] | .383 |
| Height, cm | 170 [163–173] | 167 [165–175] | .821 | 170 [165–174] | 167 [161–169] | .179 |
| History of CRcl < 50 ml/min, n (%) | 8 (28.6) | 5 (11.4) | .125 | 2 (12.5) | 2 (12.5) | 1 |
| History of diabetes mellitus, n (%) | 10 (35.7) | 11 (25.0) | .478 | 4 (25.0) | 6 (37.5) | .704 |
| History of hypertension | 10 (35.7) | 23 (52.3) | .258 | 5 (31.3) | 8 (50.0) | .473 |
| Heart failure (EF < 50%), n (%) | 18 (64.3) | 16 (36.4) | .038 | 12 (75.0) | 4 (25.0) | .012 |
| CPB during surgery, n (%) | 9 (32.1) | 25 (56.8) | .071 | 7 (43.8) | 7 (43.8) | 1 |
| VAD, n (%) | 7 (25) | 7 (15.9) | .519 | 5 (31.3) | 1 (6.3) | .172 |
| Circulatory shock at baseline, n (%) | 8 (28.6) | 21 (47.8) | .171 | 4 (25.0) | 9 (56.3) | .149 |
| Others nephrotoxic agentsa, n (%) | 18 (64.3) | 29 (65.9) | .910 | 9 (56.3) | 11 (68.7) | .716 |
| SAPS II score at ICU admission | 44.5 [35.3–57.8] | 45.5 [34.0–57.8] | .894 | 51.0 [38.5–61.5] | 48.0 [35.0–57.0] | .984 |
| SOFA score at baseline | 5 [2–9] | 6 [3–9] | .388 | 4 [2–7] | 6 [3–8] | .281 |
| Serum creatinine at baseline, μmol/l | 110 [77–142] | 99 [72–134] | .699 | 87 [64–126] | 94 [69–124] | .440 |
| AKI at baseline, n (%) | 7 (25.0) | 13 (29.5) | .881 | 2 (12.5) | 6 (37.5) | .220 |
| Previous antibiotic treatment, n (%) | 19 (67.8) | 24 (54.5) | .381 | 8 (50) | 8 (50) | 1 |
| GPC bacteraemia, n (%) | 16 (57.1) | 12 (27.3) | .022 | 11 (68.8) | 10 (62.5) | .710 |
Quantitative data are expressed as median [interquartile range]. Baseline is the time of treatment initiation
aWithin 2 days before or after initiation of treatment
DAP daptomycin, VAN vancomycin, CRcl creatinine clearance, EF ejection fraction, CPB cardiopulmonary bypass, VAD ventricular assist device, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment, AKI acute kidney injury, GPC Gram positive cocci